As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved to treat pediatric patients as well as adults with the HIV virus, specifically children ages six and older. Etravirine is best if used on treatment-experienced children who have HIV that are resistant to nonnucleoside reverse transcriptase inhibitors, and used in combination with other antiretroviral treatments. Even with the new pediatric indication for Etravirine in late 2012, this powerhouse AIDS medication has long been a reliable and effectual part of the cocktail of drugs used to treat the HIV virus.
Recent research presented at the 14th International Workshop on Clinical Pharmacology of HIV Therapy on April 23, 2013 offered reassurance regarding the continued efficacy and reliability of Etravirine. Results from the “Intelence aNd PRezista Once A Day Study”, also coined INROADS, aimed to assess the effectiveness, pharmacokinetics, safety and tolerability of Etravirine, along with combination treatment. The dosage of Etravirine was a once daily 400 milligram dose, and it was given adjunctively with 800 milligrams of Darunavir and 100 milligrams of Ritonavir. The patient population for this particular study involved 49 adults with who were treatment-naive with certain transmitted resistance mutations, or patients who had been previously treated with antiretrovirals. At the conclusion of the study researchers concluded that they felt confident that the dosages were effectual for containing viral loads, and reaffirmed their faith in Etravirine as a substantial and worthy treatment for the HIV virus. While Etravirine is not currently approved as a once a day dose, researchers are now looking toward achieving this status change, citing the positive study results as proof.
LGM Pharma provides Etravirine for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.